The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Aberrant wound-healing responses to injury have been implicated in the development of pulmonary fibrosis, but the mediators directing these pathologic responses have yet to be fully identified. We show that lysophosphatidic acid levels increase in bronchoalveolar lavage fluid following lung injury in the bleomycin model of pulmonary fibrosis, and that mice lacking one of its receptors, LPA1, are markedly protected from fibrosis and mortality in this model. The absence of LPA1 led to reduced fibroblast recruitment and vascular leak, two responses that may be excessive when injury leads to fibrosis rather than to repair, whereas leukocyte recruitment was preserved during the first week after injury. In persons with idiopathic pulmonary fibrosis, lysophosphatidic acid levels in bronchoalveolar lavage fluid were also increased, and inhibition of LPA1 markedly reduced fibroblast responses to the chemotactic activity of this fluid. LPA1 therefore represents a new therapeutic target for diseases in which aberrant responses to injury contribute to fibrosis, such as idiopathic pulmonary fibrosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bexotegrast is a small molecule dual inhibitor of αvβ6 and αvβ1[105]. Cumulative data of 630 patients composed of several phase 1 and 2 trials investigating αvβ6 and αvβ1 in both IPF and primary sclerosing cholangitis demonstrated mild adverse effects in the bexotegrast group (headache, diarrhea, and nausea), with diarrhea being the most common in phase 2 studies”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [104]
In the citing paper
“In pulmonary fi brosis, lysophosphatidic acid receptor 1 (LPA1) activation is associated with fi broblast recruitment, activation/proliferation, and survival, as well as epithelial cell apoptosis, all of which drive lung fi brosis progression (8, 9).”
From Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. (2025) · cites this paper as [8]
In the citing paper
“LPA1 is known to be involved in in fl ammatory responses of vascular endothelium and fi broblast recruitment”
From Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. (2025) · cites this paper as [8]
In the citing paper
“and LPA1 de fi ciency attenuated fi broblast recruitment in a murine model of lung fi brosis (8).”
From Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. (2025) · cites this paper as [8]
Citations
Cites
Wound Healing--Aiming for Perfect Skin Regeneration
Martin, P. (1997) · Science · doi:10.1126/science.276.5309.75 · Cited by 4,804 · cited 1×
“After cutaneous injury, fibroblasts migrate into the provisional fibrin matrix of the wound clot during granulation tissue formatio”
BackgroundRidley, A. J., & Hall, A. (1992) · Cell · doi:10.1016/0092-8674(92)90163-7 · Cited by 4,468
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Chemokines — Chemotactic Cytokines That Mediate Inflammation
Luster, A. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802123380706 · Cited by 3,630 · cited 1×
“1a ), indicating that the relevant fibroblast receptor(s) signal through the Gα i class of G proteins, a hallmark of the chemoattractant subfamily of GPCR”
BackgroundSelf-citationMunger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
The epigenetic progenitor origin of human cancer
Feinberg, A. P., Ohlsson, R., & Henikoff, S. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1748 · Cited by 1,853 · cited 1×
“Epigenetic processes, such as DNA or histone methylation and histone acetylation, produce heritable but potentially reversible changes in DNA or its associated proteins, and are prominent in developmental processes and oncogenesis ( 1 ).”
BackgroundSelman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786 · cited 1×
“In the lung, aberrant wound-healing responses to injury are thought to contribute to the pathogenesis of idiopathic pulmonary fibrosis (IPF”
BackgroundSelf-citationCirculating Fibrocytes Define a New Leukocyte Subpopulation That Mediates Tissue Repair
Bucala, R., Spiegel, L. A., Chesney, J., Hogan, M., & Cerami, A. (1994) · Molecular Medicine · doi:10.1007/bf03403533 · Cited by 1,308
Kim, K. K., Kugler, M. C., Wolters, P. J., Robillard, L., Galvez, M. G., Brumwell, A. N., Sheppard, D., & Chapman, H. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605669103 · Cited by 1,257 · cited 1×
“Fibrin deposition in injured airspaces may contribute to fibroblast accumulation both by providing a provisional matrix for fibroblast migration and by promoting epithelial-to-mesenchymal transitio”
BackgroundThe emerging role of lysophosphatidic acid in cancer
Mills, G. B., & Moolenaar, W. H. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1143 · Cited by 1,094 · cited 1×
“LPA has been shown to induce the invasion of cancer cells across tissue barriers, promoting metastasi”
Background
Cited by
Items 501–600 of 857
Expression of autotaxin and acylglycerol kinase in proliferative vitreoretinal epiretinal membranes
El‐Asrar, A. M. A., Missotten, L., & Geboes, K. J. (2011) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2011.02303.x · Cited by 17
“increased, and inhibition of LPA1 receptor markedly reduced fibroblast responses to the chemotactic activity of this fluid (Tager et al. 2008).”
BackgroundInfluentialHelmer, E., Willson, A., Brearley, C. J., Westerhof, M., Delage, S., Shaw, I., Cooke, R., & Sidhu, S. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1021 · Cited by 14
The matricellular protein CCN3 supports lung endothelial homeostasis and function
Betageri, K. R., Link, P. A., Haak, A. J., Ligresti, G., Tschumperlin, D. J., & Caporarello, N. (2022) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00248.2022 · Cited by 15
Lysophosphatidic acid metabolism and signaling in heart disease
Jose, A., Fernando, J. J., & Kienesberger, P. C. (2024) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2024-0077 · Cited by 14
Lysophospholipids in Lung Inflammatory Diseases
Zhao, J., & Zhao, Y. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-63046-1_20 · Cited by 14
Konopa, A., Meier, M. A., Franz, M. J., Bernardinelli, E., Voegele, A.-L., Atreya, R. N., Ribback, S., Roessler, S. K., Aigner, A. M., Singer, K., et al. (2022) · Oncogenesis · doi:10.1038/s41389-022-00445-z · Cited by 18
“LPAR1 knockout mice show a reduction in both renal and pulmonary fibrosis [23, 24].”
BackgroundDevelopment of a phosphatase-resistant, l -tyrosine derived LPA1/LPA3 dual antagonist
East, J. E., Carter, K. M., Kennedy, P., Schulte, N. A., Toews, M. L., Lynch, K. R., & Macdonald, T. L. (2011) · MedChemComm · doi:10.1039/c0md00273a · Cited by 14
Newer developments in idiopathic pulmonary fibrosis in the era of anti-fibrotic medications
NAIR, G. B., Matela, A., Kurbanov, D., & Raghu, G. (2016) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2016.1177461 · Cited by 14
“and inhibition of LPA1 receptor markedly reduced fibroblast responses to chemotactic activity [121].”
BackgroundMeng, G., Wuest, M., Tang, X., Dufour, J. H., McMullen, T. P. W., Wuest, F. R., Murray, D. L., & Brindley, D. N. (2020) · Cancers · doi:10.3390/cancers12040999 · Cited by 14
“Numerous studies employing genetic or pharmacological modulation of the ATX-LPA pathway in mice treated with the radiomimetic drug BLM have established an important role for LPA signaling through the LPA1 receptor in the DNA damage-mediated fibrosis of organs such as lung [14,19,22,23,57,73,74].”
BackgroundResultInfluentialLI, J., Wang, G., & Sun, X. (2014) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.1916 · Cited by 14
“In vitro studies also showed that S1P and LPA activated the recruitment, activation and differentiation of lung fibroblasts through their G protein-coupled receptors (4,7,9).”
Contreras, O., & Harvey, R. P. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1017660 · Cited by 13
“The involvement of the ENPP2-LPA-LPAR axis in inflammation and fibrosis is not new and several studies have shown its crucial participation (Tager et al., 2008; Castelino et al., 2011; Gan et al., 2011; Sakai et al., 2013; Ohashi and Yamamoto, 2015; He et al., 2018; Ninou et al., 2018); however,…”
BackgroundSong, Y., Ali, F. N., Ye, Z., Zarzoso, J., Rogowski, J., Sun, Y., & Xin, Y. (2024) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1417 · Cited by 13
“11,20 Preclinical and clinical studies of LPAR1 deletion and antagonism have demonstrated attenuated dermal fibrosis in mice and reduced fibroblast responses in bronchoalveolar lavage samples from patients with IPF.”
BackgroundLPA1 antagonist-derived LNPs deliver A20 mRNA and promote anti-fibrotic activities
Yan, J., Kang, D. D., Wang, C., Hou, X., Du, S., Wang, S., Xue, Y., Liu, Z., Li, H., Zhong, Y., et al. (2024) · Nano Research · doi:10.1007/s12274-024-6747-6 · Cited by 13
Ma, D., Tan, Z., Li, S., Zhao, B. T., Yue, L., Wei, X., Xu, S., Jiang, N., Lei, H., & Zhai, X. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02719 · Cited by 13
Shimizu, Y., Horibata, Y., Domae, M., Nakamura, Y., Yokoyama, T., Arai, R., Shiobara, T., Takemasa, A., Koike, R., Uchida, N., et al. (2025) · Respiratory Research · doi:10.1186/s12931-025-03239-0 · Cited by 13
Brooks, D. L. P., Zimmer, A. S., Wakefield, L. M., Lyle, L. T., Difilippantonio, S., Tucci, F. C., Illiano, S., Annunziata, C. M., & Steeg, P. S. (2018) · Oncotarget · doi:10.18632/oncotarget.25231 · Cited by 14
Existing and emerging treatments for idiopathic pulmonary fibrosis
Kolilekas, L., Papiris, S. A., & Bouros, D. E. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1568244 · Cited by 15
“BMS-986020 BMS-986020 is an oral antagonist of LPA receptor 1 (LPA1) that reduces pro-fibrotic and pro-inflammatory mediators in mice bleomycin model [73].”
BackgroundTaneja, A., Desrivot, J., Diderichsen, P. M., Blanqué, R., Allamassey, L., Fagard, L., Fieuw, A. M., van der Aar, E., & Namour, F. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00755-3 · Cited by 13
Boehm, T., Ristl, R., Joseph, S., Petroczi, K., Klavins, K., Valent, P., & Jilma, B. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.03.043 · Cited by 13
Lei, H., Cao, Z., Wu, H., Li, T., Wang, X., Chen, Y., Ma, E., Sun, L., & Zhai, X. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113951 · Cited by 14
Involvement of Lysophospholipids in Pulmonary Vascular Functions and Diseases
Kume, H., Harigane, R., & Rikimaru, M. (2024) · Biomedicines · doi:10.3390/biomedicines12010124 · Cited by 13
“…LPA and S1P enhance adhesion molecules in pulmonary vascular endothelial cells [13,14]. cells [13,14 levels are increased in BALFs following lung injury in a bleomycin model of LPA levels are increased in BALFs following lung injury in a bleomycin model of pulmonary fi brosis [15]. fibrosis [15].”
BackgroundInfluentialNakanaga, K., Hama, K., Kano, K., Sato, T., Yukiura, H., Inoue, A., Saigusa, D., Tokuyama, H., Tomioka, Y., Nishina, H., et al. (2014) · The Journal of Biochemistry · doi:10.1093/jb/mvt114 · Cited by 13
Yang, L., Cui, H., Wang, Z., Zhang, B., Ding, J., Liu, L., & Ding, H. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090751 · Cited by 13
“We first examined lung sections by immunohistochemical staining for S100A4, also known as fibroblast-specific protein 1,(30) a marker for lung fibroblasts.(31,32) In the wild-type lung, S100A4 resident fibroblasts were found in the adventitia of vascular vessels, as well as in the lung interstitium and along alveolar…”
Lamontagne, M., Joubert, P., Timens, W., Postma, D. S., Hao, K., Nickle, D. C., Sin, D. D., Paré, P. D., Laviolette, M., & Bossé, Y. (2016) · European Respiratory Journal · doi:10.1183/13993003.00114-2016 · Cited by 13
Recent progress in systemic sclerosis-interstitial lung disease
Castelino, F. V., & Dellaripa, P. F. (2018) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000544 · Cited by 13
Hsia, I., Asmani, M., & Zhao, R. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115194 · Cited by 12
Inhibition of LPA-LPAR1 and VEGF-VEGFR2 Signaling in IPF Treatment
Luo, Y.-L., Li, Y., Zhou, W., Wang, S., & Liu, Y. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s415453 · Cited by 12
“fibrosis.(45) Levels of LPA are elevated in bronchoalveolar lavage fluid samples from IPF patients(46) supporting the clinical relevance of this signaling pathway in IPF development.”
BackgroundInfluentialIdentification of inflammation-related biomarkers in keloids
Wang, X., Wang, X., Liu, Z., Liu, L., Zhang, J., Jiang, D., & Huang, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1351513 · Cited by 13
Kadam, A. H., & Schnitzer, J. E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212300 · Cited by 12
“BALF protein content due to bleomycin injury is characteristic of increased vascular permeability and lung damage [12,16].”
The role of vascularity and the fibrovascular interface in interstitial lung diseases
Dietrich, J., Kang, A., Tielemans, B., Verleden, S. E., Khalil, H. A., Länger, F. P., Bruners, P., Mentzer, S. J., Welte, T., Dreher, M., et al. (2025) · European Respiratory Review · doi:10.1183/16000617.0080-2024 · Cited by 15
Emerging targeted therapies in scleroderma lung and skin fibrosis
Maurer, B., & Distler, O. (2011) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2011.11.007 · Cited by 12
Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials
Sgalla, G., Lerede, M., & Richeldi, L. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1931119 · Cited by 12
“and prolonged vascular permeability [20,21].”
Shiomi, T., Boudreault, F., Padem, N., Higashiyama, S., Drazen, J. M., & Tschumperlin, D. J. (2011) · Wound Repair and Regeneration · doi:10.1111/j.1524-475x.2010.00655.x · Cited by 13
“In the lung, LPA is detectable in human bronchoalveolar lavage fluid,(8) and recent work has shown that increased LPA levels are present in pulmonary fibrosis (IPF), and contribute to lung injury and fibrosis in a murine experimental model of fibrosis.(9) The latter finding demonstrates LPA has important effects in th…”
BackgroundInfluentialAutotaxin as a novel, tissue-remodeling-related factor in regressing corpora lutea of cycling rats
Masuda, K., 悟, 治., Orino, K., Kawaminami, M., & Kurusu, S. (2013) · FEBS Journal · doi:10.1111/febs.12565 · Cited by 12
Fujisawa, Y., Matsuda, K., & Uehara, T. (2020) · Biological Chemistry · doi:10.1515/hsz-2020-0125 · Cited by 14
“As dysregulation of migration of fibroblasts leads to development of fibrosis, this can be a therapeutic target (Tager et al. 2008).”
BackgroundAntoniou, K. M., Tsitoura, E., Vasarmidi, E., Symvoulakis, E. K., Aidinis, V., Tzilas, V., Τzouvelekis, Α., & Bouros, D. E. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.12.007 · Cited by 12
Targeting the myofibroblast to improve wound healing
Hinz, B. (2016) · Elsevier eBooks · doi:10.1016/b978-1-78242-455-0.00003-3 · Cited by 13
Wu, X., Gou, H., Zhou, O., Qiu, H., Liu, H., Fu, Z., & Chen, L. (2022) · Respiratory Research · doi:10.1186/s12931-022-02192-6 · Cited by 11
Fibrosis in PCLS: comparing TGF-β and fibrotic cocktail
Machahua, C., Marti, T. M., Dorn, P., & Funke-Chambour, M. (2025) · Respiratory Research · doi:10.1186/s12931-025-03110-2 · Cited by 12
Birker, M., Boucher, M., Ranieri, G., Poirey, S., Studer, R. O., Freti, D., Schnoebelen, M., Froidevaux, S., Morrison, K., Wyss, C., et al. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103396 · Cited by 12
Dai, T., Liang, Y., Li, X., Zhao, J., Li, G., Li, Q., Xu, L., & Zhao, J. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1608750 · Cited by 12
Wu, J., Mukherjee, A., Lebman, D. A., & Fang, X. (2012) · Oncogene · doi:10.1038/onc.2012.325 · Cited by 11
“However, more recent studies of lpa 1 mice subjected to various pathophysiological conditions revealed that LPA1 is involved in initiation of neuropathic pain (8), embryonic and adult neurogenesis, and promotion of pulmonary and renal fibrosis (9, 10).”
BackgroundShuvaev, S., Knipe, R. S., Drummond, M., Rotile, N. J., Ay, İ., Weigand‐Whittier, J., Ma, H., Zhou, I. Y., Roberts, J. D., Black, K., et al. (2023) · Molecular Imaging and Biology · doi:10.1007/s11307-023-01845-2 · Cited by 11
“Lung hydroxyproline concentration was measured using a colorimetric assay as described previously [13].”
MethodSofia, C., Comes, A., Sgalla, G., & Richeldi, L. (2023) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2023.2281416 · Cited by 11
“Specifically, LPA1 appears overexpressed in lung fibrosis [66,67] and its activation can determinate fibroblast recruitment and increased fibroblast resistance to apoptosis [68].”
BackgroundWalker, N., Ibuki, Y., McLinden, A. P., Misumi, K., Mitchell, D. C., Kleer, G. G., Lock, A., Vittal, R., Sonenberg, N., Garner, A. L., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci168393 · Cited by 11
Gan, H., Mckenzie, R., Qin, H., Idell, S., & Tang, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101983 · Cited by 11
“LPA and thrombin are profibrotic factors and have been shown to play important roles in the pathogenesis of pulmonary fibrosis [29,30].”
BackgroundDevelopment of an Activity‐Based Probe for Autotaxin
Cavalli, S., Houben, A. J. S., Albers, H. M. H. G., van Tilburg, E. W., de Ru, A., Aoki, J., van Veelen, P. A., Moolenaar, W. H., & Ovaa, H. (2010) · ChemBioChem · doi:10.1002/cbic.201000349 · Cited by 11
The Clinical Utility of Soluble Serum Biomarkers in Autoimmune Pancreatitis: A Systematic Review
Dugic, A., Gil, C. V., Mellenthin, C., Vujasinović, M., Löhr, M. J., & Mühldorfer, S. (2022) · Biomedicines · doi:10.3390/biomedicines10071511 · Cited by 12
Targeting GPCRs to treat cardiac fibrosis
Zhang, H., Ren, L., & Shivnaraine, R. V. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1011176 · Cited by 14
“LPA1 is highly expressed on human primary fibroblasts, which predominantly couples to Gαq/11, Gαi/o, and Gα12/13 proteins (52).”
BackgroundKawaguchi, M., Okabe, T., Okudaira, S., Hama, K., Kano, K., Nishimasu, H., Nakagawa, H., Ishitani, R., Kojima, H., Nureki, O., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01967 · Cited by 13
“Bioengineering the lung: molecules, materials, matrix, morphology, and mechanics”
Prakash, Y. S., & Stenmark, K. R. (2012) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00020.2012 · Cited by 11
Regulation of Vascular Endothelial Barrier Integrity and Function by Lipid-Derived Mediators
Fu, P., Ramchandran, R., Dudek, S. M., Parinandi, N. L., & Natarajan, V. (2022) · Springer eBooks · doi:10.1007/978-3-031-08309-9_17 · Cited by 11
Maher, T. M., Song, J. W., Kramer, M. R., LANCASTER, L. H., Corte, T. J., Yun, J. H., Kim, K., Cho, J., Sather, L., George, P., et al. (2025) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2024-003038 · Cited by 12
Li, Q., Wong, W. R., Birnberg, A., Chakrabarti, A., Yang, X., Choy, D. F., Olsson, J. K., Verschueren, E., Neighbors, M., Sandoval, W. N., et al. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01670-9 · Cited by 11
“LPA signals through G protein-coupled LPA receptors (LPAR1–6) expressed on many tissues and immune cells [21], to regulate in cell proliferation [22], fibrosis [23], and lymphocyte homing [18, 19].”
BackgroundMelanocortin therapies to resolve fibroblast-mediated diseases
Khodeneva, N., Sugimoto, M. A., Davan-Wetton, C. S. A., & Montero‐Melendez, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1084394 · Cited by 12
“Examples of other pathways that may prevent the activation of pathogenic fibroblasts or reduce their recruitment include the inhibition of the Notch (107), JAK/STAT (108), TNF receptor (109), lysophosphatidic acid receptor 1 (LPA1) (110), RANK ligand (42) or Ca signalling (111) pathways, and on the other hand, the act…”
BackgroundArmani, E., Rizzi, A., Iotti, N., Saccani, F., Lascia, M. R. D., Tigli, L., Pappani, A., Marchini, G., Murgo, A., Capelli, A. M., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02087 · Cited by 10
Lescop, C., Brotschi, C., Williams, J. T., Sager, C. P., Birker, M., Morrison, K., Froidevaux, S., Delahaye, S., Nayler, O., & Bolli, M. H. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01826 · Cited by 10
Fan, G., Guan, X., Guan, B., Zhu, H., Pei, Y., Jiang, C., Xiao, Y., Li, Z., & Cao, F. (2024) · PLoS ONE · doi:10.1371/journal.pone.0301011 · Cited by 10
Exploring therapeutic targets for molecular therapy of idiopathic pulmonary fibrosis
Li, Y., Jiang, C., Zhu, W., Lu, S., Yu, H., & Meng, L. (2024) · Science Progress · doi:10.1177/00368504241247402 · Cited by 11
“89 In a phase II trial, the change of FVC of patients who received BMS-986020, the antagonist of the LPA1, was substantially slower than that of the placebo group.”
BackgroundPromising advances in treatments for the management of idiopathic pulmonary fibrosis
Sofia, C., Comes, A., Sgalla, G., & Richeldi, L. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2354460 · Cited by 10
“Specifically, pentraxin-2 May modulate the innate immune system via the inhibition of monocyte differentiation into macrophages, the reduction of TGF-β levels, and stopping the transition from monocytes to fibrocytes [38–40].”
BackgroundLing, N., Wei, J., Jacko, A. M., Culley, M. K., Zhao, J., Natarajan, V., Ma, H., & Zhao, Y. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.11.012 · Cited by 10
“implicating the role of LPA/LPA1 in the injury response in the lungs [39].”
Nathan, S., Zhang, H., Andreoli, M., Leopold, P. L., & Crystal, R. G. (2021) · Respiratory Research · doi:10.1186/s12931-021-01677-0 · Cited by 12
“Expression of LPAR1 and 2 was implicated since bleomycin-treated mice lacking LPAR1 or LPAR2 were protected from developing lung fibrosis [24, 30].”
BackgroundInfluentialDiet, herbs and erectile function: A good friendship!
Olabiyi, A. A., & Ajayi, K. (2022) · Andrologia · doi:10.1111/and.14424 · Cited by 14
“ADO- induced vasodilation is regulated by A2A receptor signalling, which increases intracellular adenosine monophosphate (cAMP) levels in vascular smooth muscle cells (Olsson & Pearson, 1990; Tager et al., 2008).”
BackgroundMolecular regulation of lysophosphatidic acid receptor 1 trafficking to the cell surface
Zhao, J., Wei, J., Bowser, R. K., Dong, S., Xiao, S., & Zhao, Y. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.07.005 · Cited by 10
Kassel, K. M., Dodmane, P. R., Schulte, N. A., & Toews, M. L. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.133736 · Cited by 10
“Most recently, it has been shown that LPA is increased in bronchoalveolar lavage fluid after lung injury and that mice lacking the LPA1 receptor are protected from edema, fibrosis, and mortality (Tager et al., 2008).”
BackgroundSandbo, N. K. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_8 · Cited by 13
Balupuri, A., Lee, D.-Y., Lee, M. H., Chae, S.-E., Jung, E., Kim, Y.-K., Ryu, J., & Kang, N. S. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.07.022 · Cited by 10
Taleb, S. J., Wei, J., Mialki, R. K., Dong, S., Li, Y., Zhao, J., & Zhao, Y. (2021) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29919 · Cited by 10
“The pathogenesis role of LPA/LPA1 in various diseases has been revealed.(7,8,12,12,33) LPA1 is a FIGURE 3 Peptide P1 increases LPA1 stability through mitigating its ubiquitination.”
BackgroundInfluentialYanagihara, T., Scallan, C. J., Ask, K., & Kolb, M. R. J. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.2006186 · Cited by 10
“The LPA1 receptor antagonist BMS986020 demonstrated proof of concept in patients with IPF in a 6-month phase II trial but was withdrawn from clinical development due to hepatobiliary toxicity [32].”
InfluentialTargeting the epithelial cells in fibrosis: a new concept for an old disease
Moll, S., Chaykovska, L., Meier, M., Budd, D. C., Formentini, I., Pomposiello, S. I., & Prunotto, M. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.01.006 · Cited by 12
Kassel, K. M., Schulte, N. A., & Toews, M. L. (2009) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.90446.2008 · Cited by 10
“Recent studies showing elevated levels of LPA in airway fluids in relation to lung disease in either human subjects (14, 36) or animal models (36, 39) further strengthen the evidence for LPA as a likely contributor to these diseases.”
At the frontiers of lung fibrosis therapy
(2013) · Nature Biotechnology · doi:10.1038/nbt.2687 · Cited by 10
Hoshino, Y., Okuno, T., Saigusa, D., Kano, K., Yamamoto, S., Shindou, H., Aoki, J., Uchida, K., Yokomizo, T., & Ito, N. (2022) · Institutional Repositories DataBase (IRDB) · doi:10.1096/fj.202101678r · Cited by 9
Distinct biological subtypes of chronic GVHD after pediatric hematopoietic cell transplantation
Ng, B., Harris, A. C., Abdossamadi, S., Aubert, G., Bajwa, R. P. S., Bhatia, M., Bittencourt, H. N. D. S., Buxbaum, N. P., Caywood, E., Chaudhury, S., et al. (2025) · Blood · doi:10.1182/blood.2025028625 · Cited by 10
Verçosa, B. L. A., Muniz‐Junqueira, M. I., Menezes‐Souza, D., Fujiwara, R. T., Borges, L. D. F., Melo, M. N., & Vasconcelos, A. C. (2023) · Molecular Immunology · doi:10.1016/j.molimm.2023.02.010 · Cited by 11
Meng, F., Yin, Z., Lu, F., Wang, W., & Zhang, H. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15193 · Cited by 9
“14 Recently, LPA has been proposed to promote tumor immune invasion via a mechanism similar to that of CTLA-4 and PD-1.”
BackgroundWang, C., Deng, Y., Huang, S.-Y., Liu, C.-M., Chang, H., & Man-Ying, W. (2012) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2012.04.004 · Cited by 9
Discovery of Novel Gq-Biased LPA1 Negative Allosteric Modulators
Shimizu, Y., & Nakayama, M. (2017) · SLAS DISCOVERY · doi:10.1177/2472555217691719 · Cited by 9
“Recent studies have revealed the relevance of LPA1 function to multiple human disorders, including neuropathic pain,(3) fetal hydrocephalus,(4) cancer,(1,5) and fibrosis.(6) Currently, the LPA1 antagonists BMS-986020 and SAR100842 are in clinical development for the treatment of idiopathic pulmonary fibrosis, systemic…”
BackgroundA role for bronchial epithelial autotaxin in ventilator-induced lung injury
Nikitopoulou, I., Ninou, I., Manitsopoulos, N., Dimopoulou, I., Orfanos, S. E., Aidinis, V., & Kotanidou, Α. (2021) · Intensive Care Medicine Experimental · doi:10.1186/s40635-021-00379-7 · Cited by 9
“Vascular leak has been suggested to be among the dominant pathological effects of ATX/LPA in pulmonary pathophysiology and fibrosis [8, 13], a dysfunction characterizing VILI pathogenesis [14].”
BackgroundIsshiki, T., Shimizu, H., Sakamoto, S., Yamasaki, A., Miyoshi, S., Nakamura, Y., Homma, S. A., & Kishi, K. (2022) · ERJ Open Research · doi:10.1183/23120541.00683-2021 · Cited by 9
“Mice with genetic deficiency of LPA 1 and pharmacological inhibition of LPA 1 both demonstrated protection from fibrosis in a bleomycin mouse model of pulmonary fibrosis [4, 6].”
Zhan, Z., Wei, Z., Ying, B., Chai, L., Yu, Q., Yu, X., Zhou, L., Wan, C., Fan, L., Huang, J., et al. (2022) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2022.132575 · Cited by 9
Shim, G. H., Kim, H. J., Kim, E. S., Lee, K.-Y., Kim, E.-K., & Choi, J. (2015) · Free Radical Research · doi:10.3109/10715762.2015.1073850 · Cited by 9
Familial and sporadic idiopathic pulmonary fibrosis: making the diagnosis from peripheral blood
Meltzer, E. B., Barry, W. T., Yang, I. V., Brown, K. K., Schwarz, M. I., Patel, H., Ashley‐Koch, A. E., Noble, P. W., Schwartz, D. A., & Steele, M. P. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-902 · Cited by 9
“LPA is increased in bronchoalveolar lavage fluid following lung injury in the bleomycin model of pulmonary fibrosis, and mice lacking of its receptors, LPA1, are protected from injury [20].”
BackgroundRegulation of silicosis formation by lysophosphatidic acid and its receptors
Cong, C., Mao, L., Zhang, Y., Zhao, Z., Xu, X.-X., & Zhao, J. (2014) · Experimental Lung Research · doi:10.3109/01902148.2014.920438 · Cited by 9
“LPA1/3 may also mediate the development of bleomycin-induced lung fibrosis and radiation-induced lung fibrosis [5, 6].”
BackgroundSelf-citationFisher, N. C., Hilton-Bolt, T., Edwards, M. G., Haxton, K. J., McKenzie, M. J., Allin, S. M., & Richardson, A. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4003106 · Cited by 10
A549 cells as a model to study endogenous LPA 1 receptor signaling and regulation
Carmona-Rosas, G., Alfonzo‐Méndez, M. A., Hernández-Espinosa, D. A., Romero‐Ávila, M. T., & García-Sáinz, J. A. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.09.013 · Cited by 9
Sudhadevi, T., Ha, A. W., Ebenezer, D. L., Fu, P., Putherickal, V., Natarajan, V., & Harijith, A. K. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158685 · Cited by 9
“Experimental and clinical evidence strongly suggests that LPA, through LPAR signalling, is involved in lung pathology and diseases, including airway repair and remodelling, inflammation [97], and fibrosis [102][103].”
BackgroundNews and failures from recent treatment trials in systemic sclerosis
Denton, C. P., Yee, P., & Ong, V. H. (2020) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2020.19187 · Cited by 9
“Lysophosphatidic acid receptor 1 antagonist There is strong preclinical evidence that a lysophosphatidic acid receptor 1 (LPA1) antagonist may prevent lung fibrosis (28), and this was tested in a small phase II trial that randomized patients with dcSSc to an oral LPA1 antagonist or placebo.”
BackgroundPharmacophoric Site Identification and Inhibitor Design for Autotaxin
Lee, M. H., Lee, D.-Y., Balupuri, A., Jeong, J., & Kang, N. S. (2019) · Molecules · doi:10.3390/molecules24152808 · Cited by 9
Fukiage, A., Fujino, H., Miki, D., Ishii, Y., Serikawa, M., Tsuge, M., Imamura, M., Aikata, H., Hayes, C. N., & Chayama, K. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06338-8 · Cited by 9
Involvement of lysophosphatidic acid-LPA1-YAP signaling in healthy and pathological FAPs migration
Bock-Pereda, A., Cruz-Soca, M., Gallardo, F. S., Córdova-Casanova, A., Gutiérrez‐Rojas, C., Faundez-Contreras, J., Chun, J. J. M., Casar, J. C., & Brandan, E. (2024) · Matrix Biology · doi:10.1016/j.matbio.2024.08.005 · Cited by 9
Self-citationRen, A., Moon, C., Zhang, W., Sinha, C., Yarlagadda, S., Arora, K., Wang, X., Yue, J., Parthasarathi, K., Heil-Chapdelaine, R., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.595512 · Cited by 8
“Gradient sensing is a crucial step during cell chemotaxis, and LPA has been shown to contribute to fibroblast recruitment induced by lung injury (63).”
BackgroundPeriostin Deficiency Causes Severe and Lethal Lung Injury in Mice With Bleomycin Administration
Kondoh, H., Nishiyama, T., Kikuchi, Y., Fukayama, M., Saito, M., Kii, I., & Kudō, A. (2016) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155416652611 · Cited by 8
“Louis, MO) by using a previously described technique.(33) Briefly, 8-week-old mice were injected intravenously with Evans blue dye (20 mg/kg).”
BackgroundMethodLPA and Autotaxin: Potential Drug Targets in Asthma?
Georas, S. N. (2021) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-021-01023-7 · Cited by 8
Yang, L., Shu, P., Wu, N., Hu, M., & Luo, Z. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106552 · Cited by 8
Large-Scale Synthesis of LPA1-Receptor Antagonist ACT-1016-0707
Davenport, R., Masse, F., Prud’homme, A., Bürki, C., Dörrwächter, P., Künzli, M., D’Aiuto, F., Bolli, M. H., & Schäfer, G. (2024) · Organic Process Research & Development · doi:10.1021/acs.oprd.3c00423 · Cited by 8
Tang, D. T. Y., Du, Z., Yang, K. S., Bestvater, B. P., Kaplan, J. A., Neubig, M. E., Olen, C. L., Phillips, B., Wang, P., Hudson, T. E., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02090 · Cited by 8
(2014) · Receptors & Clinical Investigation · doi:10.14800/rci.193 · Cited by 8
“LPA1 appears to be involved in renal [10] and lung [11, 12] fibrosis, and in ovarian [18, , pancreatic [19, 20] and breast [15, 18] cancer, also increasing hepatocellular carcinoma cell-invasion ([21]).”
Identification of a novel class of autotaxin inhibitors through cross-screening
Castagna, D., Duffy, E., Semaan, D., Young, L., Pritchard, J. M., Macdonald, S. J. F., Budd, D. C., Jamieson, C., & Watson, A. J. B. (2015) · MedChemComm · doi:10.1039/c5md00081e · Cited by 8
Szóstek-Mioduchowska, A. Z., Leciejewska, N., Zelmańska, B., Staszkiewicz‐Chodor, J., Ferreira-Dias, G. M., & Skarzynski, D. J. (2020) · BMC Veterinary Research · doi:10.1186/s12917-020-02562-6 · Cited by 8
Metadata
- Authors
- Tager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., Hart, W. K., Pardo, A., Blackwell, T. S., Xu, Y., Chun, J., & Luster, A. D.
- Affiliations
- Harvard University (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Indiana University Indianapolis (US)
- Vanderbilt University (US)
- Universidad Nacional Autónoma de México (MX)
- Scripps Research Institute (US)
- Corresponding author
- Luster, Andrew D
- ORCID
- Venue
- Nature Medicine
- Published
- 2007-12-09
- Volume
- 14
- Issue
- 1
- Pages
- 45-54
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2131032222
- Cited by
- 823
- References
- 54
- Citations by year
- 2026: 24 · 2025: 49 · 2024: 50 · 2023: 49 · 2022: 51 · 2021: 61 · 2020: 55 · 2019: 38 · 2018: 36 · 2017: 47 · 2016: 49 · 2015: 41 · 2014: 51 · 2013: 49 · 2012: 53
- FWCI
- 23.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Lung Association
- National Institutes of Health (5r01ca069212-18)
- National Institute of Mental Health (K02 MH01723, R01MH051699, K02MH001723, R01MH-51699)
- National Cancer Institute (R01CA69212, R01-CA89228, R01CA095042, R01CA089228)
- National Institute of Neurological Disorders and Stroke (R01NS048478)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- lysophosphatidic acid, LPA1 receptor, pulmonary fibrosis, idiopathic pulmonary fibrosis, lung injury, fibroblast recruitment, vascular leakage, bleomycin-induced fibrosis, bronchoalveolar lavage fluid, wound healing, chemotaxis, therapeutic target
- MeSH terms
- Animals, Bleomycin, Bronchoalveolar Lavage Fluid, Female, Fibroblasts, Leukocytes, Lung, Lysophospholipids, Male, Mice, Inbred C57BL, Models, Biological, Pulmonary Fibrosis, Mice, Knockout, Receptors, Lysophosphatidic Acid, Mice, Lung Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.